Suspension of trading
Valuation Forte Biosciences
Stocks
FBRX
US34962G2084
Biotechnology & Medical Research
|
Market Closed -
Nasdaq
21:00:00 26/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 76.99 USD | +0.03% |
|
+0.09% | +182.32% |
| 08-27 | Argenx SE completed the acquisition of Forte Biosciences, Inc.. | CI |
| 08-27 | Argenx Completes Acquisition of Forte Biosciences | MT |
Company Valuation: Forte Biosciences
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,939 | - | - |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 298.77% | - | - |
| Enterprise Value (EV) | 31.57 | 21 | 29.86 | 145.2 | 486.3 | 1,939 | 1,939 | 1,939 |
| Change | - | -33.49% | 42.17% | 386.3% | 234.91% | 298.77% | 0% | 0% |
| P/E | -1.38x | -1.25x | - | -1.87x | -5.79x | -17.2x | -18.9x | -18.5x |
| PBR | - | - | - | - | - | - | - | - |
| PEG | - | 0x | - | - | 0.1x | 3.52x | 2.09x | -7.94x |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / EBIT | - | - | - | -0x | -0x | -21.3x | -18.1x | -15.2x |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Dividend per Share 2 | - | - | - | - | - | - | - | - |
| Rate of return | - | - | - | - | - | - | - | - |
| EPS 2 | -38.75 | -20 | - | -12.17 | -4.71 | -4.48 | -4.075 | -4.17 |
| Distribution rate | - | - | - | - | - | - | - | - |
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | - | - | - | -36.6 | -70.66 | -91.11 | -107.4 | -127.6 |
| Net income 1 | -21.71 | -13.88 | - | -35.48 | -69.38 | -91.11 | -107.4 | -127.6 |
| Net Debt | - | - | - | - | - | - | - | - |
| Reference price 2 | 53.50 | 25.00 | 20.54 | 22.71 | 27.27 | 76.99 | 76.99 | 76.99 |
| Nbr of stocks (in thousands) | 590 | 840 | 1,453 | 6,393 | 17,831 | 25,186 | - | - |
| Announcement Date | 31/03/22 | 31/03/23 | 18/03/24 | 28/03/25 | 31/03/26 | - | - | - |
1USD in Million2USD
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 20.59x | 7.25x | 14.66x | 1.42% | 69.54B | |
| 36.89x | 9.62x | 29.41x | 0.04% | 64.97B | |
| 30.69x | 6.58x | 17.2x | -.--% | 26.51B | |
| -74.93x | 13.98x | -67.43x | -.--% | 25.89B | |
| -15.61x | 5.94x | -7.46x | -.--% | 25.64B | |
| 58.27x | 21.67x | 43.95x | 0.26% | 20.22B | |
| 27.27x | 5.11x | 16.98x | -.--% | 19.98B | |
| 1415.29x | 39.34x | 858.54x | -.--% | 15.69B | |
| 16.84x | 5x | 11.66x | -.--% | 13.49B | |
| Average | 168.37x | 12.72x | 101.95x | 0.19% | 31.33B | |
| Weighted average by Cap. | 93.83x | 10.79x | 57.82x | 0.38% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
- Stock Market
- Stocks
- FBRX Stock
- Valuation Forte Biosciences
Select your edition
All financial news and data tailored to specific country editions
